Compare APYX & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APYX | CCCC |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 185.1M |
| IPO Year | 1995 | 2020 |
| Metric | APYX | CCCC |
|---|---|---|
| Price | $3.27 | $3.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.00 | ★ $12.20 |
| AVG Volume (30 Days) | 90.9K | ★ 2.0M |
| Earning Date | 04-03-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.40 | 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $6.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $0.83 | $1.09 |
| 52 Week High | $4.50 | $3.64 |
| Indicator | APYX | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 72.10 |
| Support Level | $3.30 | $1.96 |
| Resistance Level | $4.40 | N/A |
| Average True Range (ATR) | 0.21 | 0.27 |
| MACD | -0.06 | 0.12 |
| Stochastic Oscillator | 19.39 | 92.71 |
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.